Danicamtiv

DB18962InvestigationalSmall molecule

Danicamtiv is under investigation in clinical trial NCT04572893 (Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities).

Mechanism: Pharmacologically active on Myosin-7
Curator reviewed
Formula / weight: C₁₆H₂₀F₃N₅O₄S · 435.42 g/mol (avg)
Also known as: 1-piperidinecarboxamide, 4-((1r)-1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-3-isoxazolyl- · 4-((1r)-1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(1,2-oxazol-3-yl)piperidine-1-carboxamide
Code names: MYK-491 · SAR-440181

Resolves to

Compound

UNII7B2CS922HICAS1970972-74-7ChEMBLCHEMBL4594304

Structure

InChIKeyNREKKBAMVWQRES-MRXNPFEDSA-NSMILESCN1C=C(C(=N1)C(F)F)S(=O)(=O)[C@@](C)(F)C1CCN(CC1)C(=O)NC1=NOC=C1

Targets

P12883MYH7

What you can answer from here — as of August 25, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

6Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Danicamtiv, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account